BASICS OF DEVELOPMENT OF NEW ANTIFUNGAL AGENTS IN OPHTHALMOLOGY: A REVIEW

Authors

  • ILYA KURGUZOV Center for Master's Programs, I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia https://orcid.org/0009-0002-1275-2499
  • IRINA LOGUNKOVA A. P. Nelyubin Institute of Pharmacy, I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia
  • ELENA BAKHRUSHINA A. P. Nelyubin Institute of Pharmacy, I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia
  • MADINA DURZHINSKAYA Department of Retinal and Optic Nerve Pathology, Federal State Budgetary Institution of Science "M.M. Krasnov Research Institute of Eye Diseases" (Krasnov Research Institute of Eye Diseases), Moscow, Russia https://orcid.org/0000-0002-3806-3985
  • ANNA PLYUKHOVA Department of Retinal and Optic Nerve Pathology, Federal State Budgetary Institution of Science "M.M. Krasnov Research Institute of Eye Diseases" (Krasnov Research Institute of Eye Diseases), Moscow, Russia
  • ALEXANDRA KURGUZOVA Department of Retinal and Optic Nerve Pathology, Federal State Budgetary Institution of Science "M.M. Krasnov Research Institute of Eye Diseases" (Krasnov Research Institute of Eye Diseases), Moscow, Russia https://orcid.org/0000-0002-3990-4491
  • MARIA NARBUT Department of Pathology of Optical Media of the Eye, Federal State Budgetary Institution of Science "M.M. Krasnov Research Institute of Eye Diseases" (Krasnov Research Institute of Eye Diseases), Moscow, Russia https://orcid.org/0000-0002-2931-0796

DOI:

https://doi.org/10.22159/ijap.2026v18i1.55104

Keywords:

Antifungal agents, Fungal keratitis, Treatment, Bioavailability, Side effects

Abstract

The aim of this work was to study the status of treatment of fungal eye infections. Recent data indicate a steady rise in diagnosed cases of fungal ocular diseases, particularly fungal keratitis - especially in developing countries. In some regions, the absence of locally available antifungal medications, despite increasing demand, contributes to this trend. Despite prolonged observation and efforts to combat fungal eye diseases, the global availability of antifungal drugs remains limited, especially for local use. These drugs are an integral part of comprehensive treatment, along with systemic drugs.

The objective of this review work is to conduct a comparative analysis of molecules that have been evaluated in terms of antifungal activity, bioavailability, efficacy, and safety, considering the long duration of treatment and, consequently, increased risks of side effects.

For this purpose, a comprehensive review was conducted of materials published between 2015 and 2025 in international scientific databases, including PubMed, Scopus, Google Scholar, and ResearchGate. The search strategy was designed to capture relevant studies on antifungal ophthalmic therapies, dosage forms, and active pharmaceutical ingredients used in the treatment of fungal keratitis. Based on the reviewed literature, a SWOT analysis was performed, for the first time in this context, to systematically evaluate the strengths, weaknesses, opportunities, and threats associated with the principal dosage forms of ophthalmic antifungal drugs. This novel analytical approach enabled the identification of key directions for enhancing therapeutic efficacy, improving formulation design, and addressing clinical and regulatory gaps in the management of fungal ocular infections.

The presented data can serve as a foundation for the development of improved drug formulations and delivery systems targeted directly to the affected ocular tissues-without preservatives, with controlled drug release-thereby enhancing treatment effectiveness, minimizing drug loss, and reducing patient risks associated with side effects and antifungal resistance. Furthermore, these advancements have the potential to significantly improve patient quality of life and increase the likelihood of full recovery, without irreversible visual impairment.

References

1. Burton MJ, Ramke J, Marques AP, Bourne RRA, Congdon N, Jones I, Ah Tong BAM, Arunga S, Bachani D, Bascaran C, Bastawrous A, Blanchet K, Braithwaite T, Buchan JC, Cairns J, Cama A, Chagunda M, Chuluunkhuu C, Cooper A, Crofts-Lawrence J, Dean WH, Denniston AK, Ehrlich JR, Emerson PM, Evans JR, Frick KD, Friedman DS, Furtado JM, Gichangi MM, Gichuhi S, Gilbert SS, Gurung R, Habtamu E, Holland P, Jonas JB, Keane PA, Keay L, Khanna RC, Khaw PT, Kuper H, Kyari F, Lansingh VC, Mactaggart I, Mafwiri MM, Mathenge W, McCormick I, Morjaria P, Mowatt L, Muirhead D, Murthy GVS, Mwangi N, Patel DB, Peto T, Qureshi BM, Salomão SR, Sarah V, Shilio BR, Solomon AW, Swenor BK, Taylor HR, Wang N, Webson A, West SK, Wong TY, Wormald R, Yasmin S, Yusufu M, Silva JC, Resnikoff S, Ravilla T, Gilbert CE, Foster A, Faal HB. The Lancet Global Health Commission on Global Eye Health: vision beyond 2020. Lancet Glob Health. 2021 Apr;9(4):e489-e551. doi: 10.1016/S2214-109X(20)30488-5. Epub 2021 Feb 16. PMID: 33607016; PMCID: PMC7966694.

2. GBD 2019 Blindness and Vision Impairment Collaborators; Vision Loss Expert Group of the Global Burden of Disease Study. Causes of blindness and vision impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to VISION 2020: the Right to Sight: an analysis for the Global Burden of Disease Study. Lancet Glob Health. 2021 Feb;9(2):e144-e160. doi: 10.1016/S2214-109X(20)30489-7. Epub 2020 Dec 1. Erratum in: Lancet Glob Health. 2021 Apr;9(4):e408. doi: 10.1016/S2214-109X(21)00050-4. PMID: 33275949; PMCID: PMC7820391.

3. Whitcher JP, Srinivasan M. Corneal ulceration in the developing world--a silent epidemic. Br J Ophthalmol. 1997 Aug;81(8):622-3. doi: 10.1136/bjo.81.8.622. PMID: 9349145; PMCID: PMC1722289.

4. Taipale J, Mikhailova A, Ojamo M, Nättinen J, Väätäinen S, Gissler M, Koskinen S, Rissanen H, Sainio P, Uusitalo H. Low vision status and declining vision decrease Health-Related Quality of Life: Results from a nationwide 11-year follow-up study. Qual Life Res. 2019 Dec;28(12):3225- 3236. doi: 10.1007/s11136-019-02260-3. Epub 2019 Aug 10. PMID: 31401749; PMCID: PMC6863947.

5. Heesterbeek TJ, van der Aa HPA, van Rens GHMB, Twisk JWR, vanNispen RMA. The incidence and predictors of depressive and anxiety symptoms in older adults with vision impairment: a longitudinal prospective cohort study. OphthalmicPhysiolOpt. 2017 Jul;37(4):385-398. doi: 10.1111/opo.12388. Epub 2017 May 18. PMID: 28516509.

6. Whitson HE, Cousins SW, Burchett BM, Hybels CF, Pieper CF, Cohen HJ. The combined effect of visual impairment and cognitive impairment on disability in older people. J AmGeriatrSoc. 2007 Jun;55(6):885–91. doi: 10.1111/j.1532-5415.2007.01093.x. PMID: 17537089.

7. Yan C, Zhao H, Pan Q, Xie X, Chen K, Zhang L. Novel treatments for bacterial keratitis: A review. Int J Pharm. 2025 Aug 20;681:125793. doi: 10.1016/j.ijpharm.2025.125793. Epub 2025 May 28. PMID: 40446871.

8. Stapleton F. The epidemiology of infectious keratitis. Ocul Surf. 2023 Apr;28:351-363. doi: 10.1016/j.jtos.2021.08.007. Epub 2021 Aug 19. PMID: 34419639.

9. Ting DSJ, Ho CS, Deshmukh R, Said DG, Dua HS. Infectious keratitis: an update on epidemiology, causative microorganisms, risk factors, and antimicrobial resistance. Eye (Lond). 2021 Apr;35(4):1084-1101. doi: 10.1038/s41433-020-01339-3. Epub 2021 Jan 7. Erratum in: Eye (Lond). 2021 Oct;35(10):2908. doi: 10.1038/s41433-021-01568-0. PMID: 33414529; PMCID: PMC8102486.

10. Ilyas M, Stapleton F, Willcox MDP, Henriquez F, Peguda HK, Rayamajhee B, Zahid T, Petsoglou C, Carnt NA. Epidemiology of and Genetic Factors Associated with Acanthamoeba Keratitis. Pathogens. 2024 Feb 4;13(2):142. doi: 10.3390/pathogens13020142. PMID: 38392880; PMCID: PMC10892102.Centers for Disease Control and Prevention. Fungal eye infections: about fungal eye infections [Internet]. Atlanta (GA): CDC; 2024 Apr 24 [cited 2025 Jul 23]. Available from: https://www.cdc.gov/fungal-eye-infections/about/index.html

12. Burton MJ, Pithuwa J, Okello E, Afwamba I, Onyango JJ, Oates F, Chevallier C, Hall AB. Microbial keratitis in East Africa: why are the outcomes so poor? Ophthalmic Epidemiol. 2011 Aug;18(4):158-63. doi: 10.3109/09286586.2011.595041. PMID: 21780874; PMCID: PMC3670402.13. Brown L, Kamwiziku G, Oladele RO, Burton MJ, Prajna NV, Leitman TM, Denning DW. The Case for Fungal Keratitis to Be Accepted as a Neglected Tropical Disease. J Fungi (Basel). 2022 Oct 5;8(10):1047. doi: 10.3390/jof8101047. PMID: 36294612; PMCID: PMC9605065.

14. Hoffman JJ, Burton MJ, Leck A. Mycotic Keratitis-A Global Threat from the Filamentous Fungi. J Fungi (Basel). 2021 Apr 3;7(4):273. doi: 10.3390/jof7040273. PMID: 33916767; PMCID: PMC8066744.

15. Ali Shah SI, Shah SA, Rai P, Katpar NA, Abbasi SA, Soomro AA. Visual outcome in patients of keratomycosis, at a tertiary care centre in Larkana, Pakistan. J Pak Med Assoc. 2017 Jul;67(7):1035-1038. PMID: 28770882.

16. Roth M, Holtmann C, Daas L, Kakkassery V, Kurzai O, Geerling G; and German Fungal Keratitis Registry Study Group. Results From the German Fungal Keratitis Registry: Significant Differences Between Cases With and Without a History of Contact Lens Use. Cornea. 2021 Nov 1;40(11):1453-1461. doi: 10.1097/ICO.0000000000002705. PMID: 34633358...

17. Tananuvat N, Upaphong P, Tangmonkongvoragul C, Niparugs M, Chaidaroon W, Pongpom M. Fungal keratitis at a tertiary eye care in Northern Thailand: Etiology and prognostic factors for treatment outcomes. J Infect. 2021 Jul;83(1):112-118. doi: 10.1016/j.jinf.2021.05.016. Epub 2021 May 24. PMID: 34038772.

18. Brown L, Leck AK, Gichangi M, Burton MJ, Denning DW. The global incidence and diagnosis of fungal keratitis. Lancet Infect Dis. 2021 Mar;21(3):e49-e57. doi: 10.1016/S1473-3099(20)30448-5. Epub 2020 Oct 22. PMID: 33645500.

19. Yu B, Wang Q, Zhang L, Lin J, Feng Z, Wang Z, Gu L, Tian X, Luan S, Li C, Zhao G. Ebselen improves fungal keratitis through exerting anti-inflammation, anti-oxidative stress, and antifungal effects. Redox Biol. 2024 Jul;73:103206. doi: 10.1016/j.redox.2024.103206. Epub 2024 May 23. PMID: 38796864; PMCID: PMC11152752.

20. Benedict K, Gold JAW, Smith DJ. Prevalence and Features of Fungal Keratitis Among US Patients With Commercial Health Insurance. JAMA Ophthalmol. 2024 Apr 1;142(4):386-388. doi: 10.1001/jamaophthalmol.2023.6825. PMID: 38358752; PMCID: PMC10870225.

21. Rathore K. bala, Dange K. J, Gaurav A. Patil. Practise and use of over-the-counter topical and traditional eye medicines and their effects in fungal keratitis cases in tertiary teaching hospital in Northern India. Asian J PharmClin Res. 2024 Mar;17(3):103-6. doi:10.22159/ajpcr.2024.v17i3.49534.

22. Bongomin F, Kwizera R, Namusobya M, van Rhijn N, Andia-Biraro I, Kirenga BJ, Meya DB, Denning DW. Re-estimation of the burden of serious fungal diseases in Uganda. Ther Adv Infect Dis. 2024 Feb 6;11:20499361241228345. doi: 10.1177/20499361241228345. PMID: 38328511; PMCID: PMC10848809.

23. Boakye-Yiadom E, Odoom A, Osman AH, Ntim OK, Kotey FCN, Ocansey BK, Donkor ES. Fungal Infections, Treatment and Antifungal Resistance: The Sub-Saharan African Context. Ther Adv Infect Dis. 2024 Nov 13;11:20499361241297525. doi: 10.1177/20499361241297525. PMID: 39544852; PMCID: PMC11562003.

24. Bongomin F, Gago S, Oladele RO, Denning DW. Global and Multi-National Prevalence of Fungal Diseases-Estimate Precision. J Fungi (Basel). 2017 Oct 18;3(4):57. doi: 10.3390/jof3040057. PMID: 29371573; PMCID: PMC5753159.

25. Gopinathan U, Garg P, Fernandes M, Sharma S, Athmanathan S, Rao GN. The epidemiological features and laboratory results of fungal keratitis: a 10-year review at a referral eye care center in South India. Cornea. 2002 Aug;21(6):555-9. doi: 10.1097/00003226-200208000-00004. PMID: 12131029.

26. Donovan C, Arenas E, Ayyala RS, Margo CE, Espana EM. Fungal keratitis: Mechanisms of infection and management strategies. SurvOphthalmol. 2022 May-Jun;67(3):758-769. doi: 10.1016/j.survophthal.2021.08.002. Epub 2021 Aug 20. PMID: 34425126; PMCID: PMC9206537.

27. Maier P, Betancor PK, Reinhard T. Contact Lens–Associated Keratitis—an Often Underestimated Risk. DtschArztebl Int. 2022 Oct 7;119(40):669-674. doi: 10.3238/arztebl.m2022.0281. PMID: 35912449; PMCID: PMC9830382.

28. Aldave AJ, DeMatteo J, Glasser DB, Tu EY, Iliakis B, Nordlund ML, Misko J, Verdier DD, Yu F. Report of the Eye Bank Association of America medical advisory board subcommittee on fungal infection after corneal transplantation. Cornea. 2013 Feb;32(2):149-54. doi: 10.1097/ICO.0b013e31825e83bf. PMID: 23051906.

29. Deka SK, Khanikar D. A study of the prescribing pattern and outcome of antimicrobials in infectious eye diseases in a tertiary care hospital. Asian J PharmClin Res. 2024 Aug;17(8):67–70. doi:10.22159/ajpcr.2024v17i8.51416.

30. Haseeb AA, Elhusseiny AM, Siddiqui MZ, Ahmad KT, Sallam AB. Fungal Endophthalmitis: A Comprehensive Review. J Fungi (Basel). 2021 Nov 22;7(11):996. doi: 10.3390/jof7110996. PMID: 34829283; PMCID: PMC8623405.

31. Long C, Liu B, Xu C, Jing Y, Yuan Z, Lin X. Causative organisms of post-traumatic endophthalmitis: a 20-year retrospective study. BMC Ophthalmol. 2014 Mar 25;14:34. doi: 10.1186/1471-2415-14-34. PMID: 24661397; PMCID: PMC3987925.

32. Sadiq MA, Hassan M, Agarwal A, Sarwar S, Toufeeq S, Soliman MK, Hanout M, Sepah YJ, Do DV, Nguyen QD. Endogenous endophthalmitis: diagnosis, management, and prognosis. J Ophthalmic Inflamm Infect. 2015 Dec;5(1):32. doi: 10.1186/s12348-015-0063-y. Epub 2015 Nov 3. PMID: 26525563; PMCID: PMC4630262.

33. Henry CR, Flynn HW Jr, Miller D, Forster RK, Alfonso EC. Infectious keratitis progressing to endophthalmitis: a 15-year study of microbiology, associated factors, and clinical outcomes. Ophthalmology. 2012 Dec;119(12):2443-9. doi: 10.1016/j.ophtha.2012.06.030. Epub 2012 Aug 1. PMID: 22858123; PMCID: PMC3490005.

34. Reginatto P, Agostinetto GJ, Fuentefria RDN, Marinho DR, Pizzol MD, Fuentefria AM. Eye fungal infections: a mini review. Arch Microbiol. 2023 May 15;205(6):236. doi: 10.1007/s00203-023-03536-6. PMID: 37183227; PMCID: PMC10183313.

35. Klotz SA, Penn CC, Negvesky GJ, Butrus SI. Fungal and parasitic infections of the eye. Clin Microbiol Rev. 2000 Oct;13(4):662-85. doi: 10.1128/CMR.13.4.662. PMID: 11023963; PMCID: PMC88956.

36. Sridhar J, Flynn HW Jr, Kuriyan AE, Miller D, Albini T. Endogenous fungal endophthalmitis: risk factors, clinical features, and treatment outcomes in mold and yeast infections. J Ophthalmic Inflamm Infect. 2013 Sep 20;3(1):60. doi: 10.1186/1869-5760-3-60. PMID: 24053550; PMCID: PMC3848556.

37. Ly V, Sallam A. Fungal Endophthalmitis. 2023 Jun 26. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. PMID: 32644683.

38. natacyn.com [Internet]. Nashville:Harrow IP, LLC; c2025 [cited 2025 Jul 23]. Available from: https://www.natacyn.com/

39. Sharma N, Bagga B, Singhal D, Nagpal R, Kate A, Saluja G, Maharana PK. Fungal keratitis: A review of clinical presentations, treatment strategies and outcomes. Ocul Surf. 2022 Apr;24:22-30. doi: 10.1016/j.jtos.2021.12.001. Epub 2021 Dec 13. PMID: 34915188.

40. Swissvision[Internet]. Panchkula: Swissvision; c2025 [cited 2025 Jul 23].Fluconazole eye drops. Available from: https://www.swissvision.in/product/fluconazole-ee-drops/

41. Al-Badriyeh D, Neoh CF, Stewart K, Kong DC. Clinical utility of voriconazole eye drops in ophthalmic fungal keratitis. Clin Ophthalmol. 2010 May 6;4:391-405. doi: 10.2147/opth.s6374. PMID: 20463910; PMCID: PMC2866570.

42. Dawa Life Sciences[Internet]. Nairobi: Dawa Limited; c2025 [cited 2025 Jul 23].Vozole eye drops. Available from: https://dawalifesciences.com/product/vozole-eye-drops/

43. Malhotra S, Khare A, Grover K, Singh I, Pawar P. Design and Evaluation of Voriconazole Eye Drops for the Treatment of Fungal Keratitis. J Pharm (Cairo). 2014;2014:490595. doi: 10.1155/2014/490595. Epub 2014 Apr 29. PMID: 26556196; PMCID: PMC4590801.

44. Taruna Swami. Clinical Profile and Evaluation of Topical Voriconazole for Management of Fungal Corneal Ulcer in North Western Rajasthan. Delhi Journal of Ophthalmology, 2018;29;35‐38; doi:10.7869/DJO.37

45. Sharma N, Bagga B, Singhal D, Nagpal R, Kate A, Saluja G, Maharana PK. Fungal keratitis: A review of clinical presentations, treatment strategies and outcomes. Ocul Surf. 2022 Apr;24:22-30. doi: 10.1016/j.jtos.2021.12.001. Epub 2021 Dec 13. PMID: 34915188.

46. Sahay P, Asif MI, Maharana PK, Titiyal JS. Periocular contact dermatitis with use of topical voriconazole 1% in mycotic keratitis. BMJ Case Rep. 2018 Sep 15;2018:bcr2018226498. doi: 10.1136/bcr-2018-226498. PMID: 30219785; PMCID: PMC6144350.

47. World Medicine Pharmaceutical Company [Internet]. Istanbul: World Medicine İlaç San. ve Tic. A.Ş.; c2025 [cited 2025 Jul 23]. Fluzamed %03 Eye drop. Available from: https://www.worldmedicine.com.tr/en/products/medicines?searchField=name&search=fluzamed

48. Lexicare Pharma [Internet]. Ankleshwar: Lexicare Pharma Pvt. Ltd; c2025 [cited cited 2025 Sep 02]. Fluconazole Eye / Ear Drop. Available from: https://www.lexicarepharma.com/fluconazole-eye-ear-drop-5422867.html

49. Inopha International [Internet]. Hangzhou: Inopha International Co, Limited; c2025 [cited cited 2025 Sep 02]. Fluconazole Eye Drops/Ophthalmic Solution 0.5%. Available from: https://www.inopha.net/fluconazole-eye-drops-ophthalmic-solution-0-5/

50. Sunways [Internet]. Mumbai: Sunways (India) Private Limited; c2025 [cited 2025 Sep 02]. ZONAT - Natamycin 5 % Eye Drops. Available from: ZonatOphthalmic Suspension | Leading Eyecare Specialists in India | Sunways India Pvt Ltd.

51. NRI Vision Care [Internet]. New Delhi: NRI Vision Care India. LTD; c2025 [cited 2025 Sep 02]. Nata-aid Eye Drop. Available from: https://nriglobalhealthcare.com/detail.jsp?cc=105&srsltid=AfmBOortFI1xF8mkMUEIplIiKbKEBkYxfH1anGHwHAo0EAnl8zHIup9c

52. MakangaraCigolo JC, Oladele RO, Kennedy SB, Bignoumba M, Hassane HM, Bucumi V, Kamwiziku G, Eduful SK, Afonso Manjate A, Isse Mohamed S, Mbise F, Shisholeka ME, Penney ROS, Orefuwa E, Denning DW. Diagnostic capacity for fungal keratitis in Africa - Survey in 50 African countries. Ocul Surf. 2023 Oct;30:139-141. doi: 10.1016/j.jtos.2023.08.010. Epub 2023 Sep 1. PMID: 37660991.

53. Khor WB, Prajna VN, Garg P, Mehta JS, Xie L, Liu Z, Padilla MDB, Joo CK, Inoue Y, Goseyarakwong P, Hu FR, Nishida K, Kinoshita S, Puangsricharern V, Tan AL, Beuerman R, Young A, Sharma N, Haaland B, Mah FS, Tu EY, Stapleton FJ, Abbott RL, Tan DT; ACSIKS Group. The Asia Cornea Society Infectious Keratitis Study: A Prospective Multicenter Study of Infectious Keratitis in Asia. Am J Ophthalmol. 2018 Nov;195:161-170. doi: 10.1016/j.ajo.2018.07.040. Epub 2018 Aug 9. PMID: 30098351.

54. Hamill RJ. Amphotericin B formulations: a comparative review of efficacy and toxicity. Drugs. 2013 Jun;73(9):919-34. doi: 10.1007/s40265-013-0069-4. PMID: 23729001.

55. Manzouri B, Vafidis GC, Wyse RK. Pharmacotherapy of fungal eye infections. Expert OpinPharmacother. 2001 Nov;2(11):1849-57. doi: 10.1517/14656566.2.11.1849. PMID: 11825321.

56. O'Day DM, Head WS, Robinson RD, Clanton JA. Corneal penetration of topical amphotericin B and natamycin. Curr Eye Res. 1986 Nov;5(11):877-82. doi: 10.3109/02713688609029240. PMID: 3490954.

57. Betbeze CM, Wu CC, Krohne SG, Stiles J. In vitro fungistatic and fungicidal activities of silver sulfadiazine and natamycin on pathogenic fungi isolated from horses with keratomycosis. Am J Vet Res. 2006 Oct;67(10):1788-93. doi: 10.2460/ajvr.67.10.1788. PMID: 17014335

58. Mascarenhas, M., Chaudhari, P. & Lewis, S.A. Natamycin Ocular Delivery: Challenges and Advancements in Ocular Therapeutics. Adv Ther. 2023 Jun; 40: 3332–3359. https://doi.org/10.1007/s12325-023-02541-x

59. Prajna NV, Krishnan T, Mascarenhas J, Rajaraman R, Prajna L, Srinivasan M, Raghavan A, Oldenburg CE, Ray KJ, Zegans ME, McLeod SD, Porco TC, Acharya NR, Lietman TM; Mycotic Ulcer Treatment Trial Group. The mycotic ulcer treatment trial: a randomized trial comparing natamycin vs voriconazole. JAMA Ophthalmol. 2013 Apr;131(4):422-9. doi: 10.1001/jamaophthalmol.2013.1497. PMID: 23710492; PMCID: PMC3769211.

60. Alakkad A, Stapleton P, Schlosser C, Murdan S, Odunze U, Schatzlein A, Uchegbu IF. Amphotericin B Polymer Nanoparticles Show Efficacy against Candida Species Biofilms. Pathogens. 2022 Jan 7;11(1):73. doi: 10.3390/pathogens11010073. PMID: 35056021; PMCID: PMC8781556.

61. Bongomin F, Oladele RO, Gago S, Moore CB, Richardson MD. A systematic review of fluconazole resistance in clinical isolates of Cryptococcus species. Mycoses. 2018 May;61(5):290-297. doi: 10.1111/myc.12747. Epub 2018 Feb 14. PMID: 29377368.

62. Schulz J, Kluwe F, Mikus G, Michelet R, Kloft C. Novel insights into the complex pharmacokinetics of voriconazole: a review of its metabolism. Drug Metab Rev. 2019 Aug;51(3):247-265. doi: 10.1080/03602532.2019.1632888. Epub 2019 Aug 16. PMID: 31215810.

63. Suman S, Kumar A, Saxena I, Kumar M. Fungal Keratitis: Recent Advances in Diagnosis and Treatment. IntechOpen; 2021 Jun [cited 2025 Sep 14]. Available from: http://dx.doi.org/10.5772/intechopen.98411 Subscription not required.

64. Habib FS, Fouad EA, Abdel-Rhaman MS, Fathalla D. Liposomes as an ocular delivery system of fluconazole: in-vitro studies. Acta Ophthalmol. 2010 Dec;88(8):901-4. doi: 10.1111/j.1755-3768.2009.01584.x. PMID: 19681761.

65. Aldosari BN, Ibrahim MA, Alqahtani Y, Abou El Ela AESF. Formulation and evaluation of fluconazole Nanosuspensions: In vitro characterization and transcorneal permeability studies. Saudi Pharm J. 2024 Jul;32(7):102104. doi: 10.1016/j.jsps.2024.102104. Epub 2024 May 16. PMID: 38841107; PMCID: PMC11152688.

66. Daneshnia F, de Almeida Júnior JN, Ilkit M, Lombardi L, Perry AM, Gao M, Nobile CJ, Egger M, Perlin DS, Zhai B, Hohl TM, Gabaldón T, Colombo AL, Hoenigl M, Arastehfar A. Worldwide emergence of fluconazole-resistant Candidaparapsilosis: current framework and future research roadmap. Lancet Microbe. 2023 Jun;4(6):e470-e480. doi: 10.1016/S2666-5247(23)00067-8. Epub 2023 Apr 27. Erratum in: Lancet Microbe. 2023 Aug;4(8):e576. doi: 10.1016/S2666-5247(23)00188-X. PMID: 37121240; PMCID: PMC10634418.

67. Sigera LSM, Denning DW. Flucytosine and its clinical usage. Ther Adv Infect Dis. 2023 Apr 5;10:20499361231161387. doi: 10.1177/20499361231161387. PMID: 37051439; PMCID: PMC10084540.

68. Bakhrushina EO, Anurova MN, Demina NB, Lapik IV, Turaeva AR, Krasniuk II. Ophthalmic drug delivery systems(Review). Drug Dev Regist. 2021;10(1):57–66. doi: 10.33380/2305-2066-2021-10-1-57-66.

69. Ivanov I, Bakhrushina E, Turaeva A, Shatalov D, Aydakova A, Akhmedova D, Kedik S. Approaches to the search of the optimum packaging of eye drops. Int J Appl Pharm. 2022;14(5):1–7. doi: 10.22159/ijap.2022v14i5.45402.

70. Wu Y, Liu Y, Li X, Kebebe D, Zhang B, Ren J, Lu J, Li J, Du S, Liu Z. Research progress of in-situ gelling ophthalmic drug delivery system. Asian J Pharm Sci. 2019 Jan;14(1):1-15. doi: 10.1016/j.ajps.2018.04.008. Epub 2018 May 24. PMID: 32104434; PMCID: PMC7032175

71. Kolawole OM, Cook MT. In situ gelling drug delivery systems for topical drug delivery. Eur J Pharm Biopharm. 2023 Mar;184:36-49. doi: 10.1016/j.ejpb.2023.01.007. Epub 2023 Jan 13. PMID: 36642283.

72. Choursiya K, Kandalkar S, Shaikh S, Gangurde P, Jadhav K, Nikam S, Bachhav R. Advancements in ocular drug delivery system: a comprehensive review. Int J Pharm Sci. 2024 May 16;2(5):758–775

73. Roche M, Lannoy D, Bourdon F, Danel C, Labalette P, Berneron C, Simon N, Odou P. Stability of frozen 1% voriconazole eye-drops in both glass and innovative containers. Eur J Pharm Sci. 2020 Jan 1;141:105102. doi: 10.1016/j.ejps.2019.105102. Epub 2019 Oct 23. PMID: 31655210.

74. Mughal S, Sakina SK. Artificial tears: Promising treatment or silent threat to public health? Health Sci Rep. 2023 Aug 24;6(8):e1508. doi: 10.1002/hsr2.1508. PMID: 37636283; PMCID: PMC10448608.

75. López-Cano JJ, González-Cela-Casamayor MA, Andrés-Guerrero V, Herrero-Vanrell R, Molina-Martínez IT. Liposomes as vehicles for topical ophthalmic drug delivery and ocular surface protection. Expert Opin Drug Deliv. 2021 Jul;18(7):819-847. doi: 10.1080/17425247.2021.1872542. Epub 2021 Jan 22. PMID: 33412914.

76. Singh M, BharadwajS, Lee KE, Kang SG. Therapeutic nanoemulsions in ophthalmic drug administration: Concept in formulations and characterization techniques for ocular drug delivery. J. Control. Release. 2020 Oct 13; 328: 895-916

77.Zhang J, Chen H, Jhanji V, Zhang B, Xie L, Dong Y. Clinical Characteristics and Treatment Outcomes of Pediatric Fungal Keratitis. Infect Drug Resist. 2025 Mar 4;18:1271-1278. doi: 10.2147/IDR.S507178. PMID: 40059941; PMCID: PMC11890013.

78. Jiang T, Tang J, Wu Z, Sun Y, Tan J, Yang L. The combined utilization of Chlorhexidine and Voriconazole or Natamycin to combat Fusarium infections. BMC Microbiol. 2020 Sep 5;20(1):275. doi: 10.1186/s12866-020-01960-y. PMID: 32891143; PMCID: PMC7487579.

79. Al-Hatmi AM, Meletiadis J, Curfs-Breuker I, Bonifaz A, Meis JF, De Hoog GS. In vitro combinations of natamycin with voriconazole, itraconazole and micafungin against clinical Fusarium strains causing keratitis. J Antimicrob Chemother. 2016 Apr;71(4):953-5. doi: 10.1093/jac/dkv421. Epub 2015 Dec 24. PMID: 26702918.

80. Hoffman JJ, Arunga S, Matayan E, Ebong A, Orishaba F, Makupa W, Elisante M, Yadav R, Das Sanyam S, Mtuy T, Macleod D, Leck A, Hu VH, Burton MJ. Randomised controlled trial of topical combination therapy chlorhexidine 0.2% and natamycin 5% versus topical natamycin 5% alone for fungal keratitis in East Africa: study protocol. Wellcome Open Res. 2025 Mar28;10:165. doi: 10.12688/wellcomeopenres.21390.1. PMID: 40495927; PMCID: PMC12149813.

Published

11-11-2025

How to Cite

KURGUZOV, I., LOGUNKOVA, I., BAKHRUSHINA, E., DURZHINSKAYA, M., PLYUKHOVA, A., KURGUZOVA, A., & NARBUT, M. (2025). BASICS OF DEVELOPMENT OF NEW ANTIFUNGAL AGENTS IN OPHTHALMOLOGY: A REVIEW. International Journal of Applied Pharmaceutics, 18(1). https://doi.org/10.22159/ijap.2026v18i1.55104

Issue

Articles In Press [Jan-Feb 2026]

Section

Review Article(s)

Copyright (c) 2025 ILYA KURGUZOV, IRINA LOGUNKOVA, ELENA BAKHRUSHINA, MADINA DURZHINSKAYA, ANNA PLYUKHOVA, ALEXANDRA KURGUZOVA, MARIA NARBUT

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Crossref
Scopus
Google Scholar
Europe PMC

Similar Articles

<< < 1 2 3 4 5 > >> 

You may also start an advanced similarity search for this article.